SINGAPORE (July 2): In May alone, medical technology company QT Vascular inked deals worth more than $98.4 million to sell the licences and rights to its coronary products to multinational medical companies. A bonanza for shareholders, however, is not quite in sight. In fact, QT Vascular has yet to distribute a dividend since its IPO on the Catalist in 2014. And, shares in the company have been trading comparatively poorly; the stock has a negative return of 96.2% over the last four years. When can shareholders expect a reward for their faith and patience in the company?

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply